Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Vinge employs additional antitrust economists to further strengthen its practice

We welcome Adam Löfquist and Carl Widstrand to our EU, Competition & Regulatory practice group.
September 30, 2021

European Commission provides sanctions compliance guidance

The European Commission has recently issued three opinions regarding the interpretation of asset freeze provisions in certain sanctions legislation pertaining to Central African Republic, Ukraine, Libya and Syria. The opinions are also of relevance for other sanctions regimes which provide for the same or similar restrictions. Therefore, their practical relevance goes far beyond the sanctions regimes in the context of which they were issued and they therefore provide for helpful guidance regarding the required thresholds for sanctions compliance generally.
September 20, 2021

Vinge contributing to International Comparative Legal Guides

Vinge’s specialists within Maritime and Transport law have been requested to contribute with a chapter explaining the Swedish legislative framework in relation to maritime law in the International Comparative Legal Guides, ICLG.
August 20, 2021